Zydus Therapeutics Inc.
Clinical trials sponsored by Zydus Therapeutics Inc., explained in plain language.
-
New hope for PBC patients: Long-Term drug trial aims to prevent liver failure
Disease control Not yet recruitingThis study tests whether the drug saroglitazar magnesium can prevent serious liver problems in people with primary biliary cholangitis (PBC), a chronic liver disease. About 386 adults already on standard treatment will receive either the drug or a placebo for several years. The g…
Phase: PHASE3 • Sponsor: Zydus Therapeutics Inc. • Aim: Disease control
Last updated Jun 15, 2026 19:03 UTC
-
New hope for PBC patients: phase 3 trial of saroglitazar launches
Disease control Not yet recruitingThis study tests a new drug, saroglitazar magnesium, in 89 adults with primary biliary cholangitis (PBC) who did not get enough benefit from or could not tolerate standard treatment (UDCA). The goal is to see if the drug can lower a key liver enzyme (alkaline phosphatase) to norm…
Phase: PHASE3 • Sponsor: Zydus Therapeutics Inc. • Aim: Disease control
Last updated Jun 10, 2026 13:27 UTC